Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

The development of anti-HER2 agents has been one of the most meaningful advancements
in the management of metastatic breast cancer, significantly improving survival outcomes …

The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …

Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer
compounds that are widely used in the treatment of hematologic malignancies and solid …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Antibody‐drug conjugates (ADCs) are a rapidly develo** therapeutic approach in cancer
treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs …

Human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is
overexpressed in 20–30% of breast cancers and is associated with poor prognosis and …

Breast cancer represents the most common cancer type and one of the major leading
causes of death in the female worldwide population. Overexpression of HER2, a …

Introduction Targeting low levels of human receptor epidermal growth factor 2 (HER2)
expression has reshaped the treatment paradigm for half of the patients with advanced …

Trastuzumab deruxtecan (T-DXd, DS-8201), an anti-HER2 antibody–drug conjugate, has
shown significant clinical benefits in HER2+ metastatic breast cancer patients. In the phase …